SCHEDULE: Vanguard Discloses 5.19% Stake in Arrowhead Pharmaceuticals

Vanguard Portfolio Management has reported beneficial ownership of 5.19% of Arrowhead Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, now beneficially owns 7,269,957 shares of Arrowhead Pharmaceuticals Inc. common stock.
• This holding represents 5.19% of the total class of securities.
• The filing indicates that Vanguard Portfolio Management has sole voting power over 123,821 shares and sole dispositive power over 7,269,957 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership by a major institutional investor, indicating a significant investment but not necessarily a change in the company's fundamental outlook or performance.

Positives

• Vanguard, a significant institutional investor, has taken a notable stake in Arrowhead Pharmaceuticals, potentially signaling confidence in the company's long-term prospects.
• The filing confirms Vanguard's substantial beneficial ownership, indicating a significant investment in the company's common stock.

Risks

• The filing does not explicitly mention any risks or challenges.
• Potential risks associated with holding a significant stake in a pharmaceutical company, such as clinical trial failures, regulatory hurdles, or competitive pressures, are not detailed in this specific filing.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by large asset managers like Vanguard in biotechnology and pharmaceutical companies are common, reflecting ongoing investment in the sector's innovation pipeline. Arrowhead Pharmaceuticals operates in the RNA interference (RNAi) therapeutics space, a field with substantial growth potential but also high development risks.

Stakeholder Impact

• Shareholders: The increased stake by a major institutional investor like Vanguard may be viewed positively, potentially increasing liquidity and signaling confidence, though it does not directly alter the company's operations or immediate financial results.
• Management: The filing confirms a significant shareholder, which is a standard aspect of public company governance.
• Creditors: No direct impact is indicated.

Next Steps

• Vanguard Portfolio Management will continue to hold the reported shares.
• Future filings will be made if Vanguard's beneficial ownership changes significantly.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Vanguard Portfolio Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Pharmaceuticals